Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T‐cell therapy for relapsed and refractory lymphoma

Ähnliche Einträge

• A new era in myeloma: the advent of chimeric antigen receptor‐T (CAR‐T) cells and bispecific antibodies
  von: P. Joy Ho, et al.
  Veröffentlicht: (2025)
• Diagnosis and management of mantle cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance
  von: Allison Barraclough, et al.
  Veröffentlicht: (2024)
• Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era
  von: Diva Baggio, et al.
  Veröffentlicht: (2024)
• Characteristics of Australian and New Zealand patients with chronic lymphocytic leukaemia: a lymphoma and related diseases registry report
  von: Arina Martynchyk, et al.
  Veröffentlicht: (2025)
• Antecedents to and outcomes of medical emergency team calls in haematology patients
  von: Abbey Willcox, et al.
  Veröffentlicht: (2025)